International Vaccine Institute
Seoul
- UEI
- GVQMF26T5L75
- CAGE
- 1T47F
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Active through
Company facts
- Self-certified in SAM.gov
- Entity structure
- International Organization
- SAM.gov registration date
- Physical address
- 1 Gwanak-ro, Gwanak-gu, Seoul, South Korea
- Website
- ivi.int
- Founded
- 1997
- Employees
- 51-250
- Estimated annual revenue
- $10M-$50M
- Industry
-
- Consumer Staples
- Food, Beverage & Tobacco
- Food Products
- Agricultural Products
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Joint U.S. - ROK respiratory surveillance services | Medical Command (Army) | $64,000 |
Grant subawards
| Prime recipient | Prime award | Amount | Awarded |
|---|---|---|---|
| The General Hospital Corporation | R01AI177075 | $888,938 |
Similar vendors
| Vendor | Location | Primary NAICS |
|---|---|---|
| Vaxcyte, Inc. | San Carlos, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Smithkline Beecham Biologicals | Rixensart, Wallonia | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| SSI Nicaragua | Managua, MN | — |
| Sciogen LLC | Los Altos, CA | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
| Soligenix, Inc. | Princeton, NJ | 541714 Research and Development in Biotechnology (except Nanobiotechnology) |
About the company
International Vaccine Institute is a nonprofit international organization that aims to discover, develop, and deliver safe, effective, and affordable vaccines for global health. Through federal grant subawards, International Vaccine Institute provides vaccine development and manufacturing services. This includes developing production and purification processes for bacterial vaccine components such as Shigella O-specific polysaccharides and recombinant tetanus toxin heavy chain protein. International Vaccine Institute also optimizes conjugation methods to combine these components into vaccine candidates. Additionally, the organization develops processes to manufacture Mycobacterium tuberculosis polysaccharide antigens and bioconjugates them to produce tuberculosis vaccine candidates. The federal prime grantees partnering with International Vaccine Institute on these vaccine development subawards include The General Hospital Corporation and The Children's Hospital Corporation.
Quick answers
Is International Vaccine Institute registered in SAM.gov?
Yes. International Vaccine Institute's SAM.gov registration is active through June 11, 2027.
What is International Vaccine Institute's most recent federal award?
International Vaccine Institute's most recent federal contract award is Joint U.S. - ROK respiratory surveillance services (W81K0218P0327), from Medical Command (Army), on September 21, 2018.
On GovTribe
See International Vaccine Institute's full federal record
- Federal contract awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors